SBIR/STTR Research Award

Polymer-Strengthened AcellularBiologically-Derived Grafts for Pelvic Organ Prolapse

Award identifier c352fc9dad6b06065b33e81558a895671f58d247a48ad7db3f7427869125de5fAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$255,971

Program and phase

SBIR · Phase I

Award year

2021

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
BioAesthetics Corporation
Proposal award date
2021-04-15
Contract end date
2022-03-31
UEI
CB6YT355CQK5
Solicitation number
PA19-272
Topic code
NICHD

Research abstract

SUMMARYPOP is an area of significant unmet medical need where patients and doctors alike are desperate for a safe and effective solution. Worldwide, over 1 billion women are impacted by POP, as it affects 33% to 50% of all women. POP symptoms can have significant negative impacts on womenandapos;s physical, mental, and sexual health, family relationships, daily living, and quality of life. Surgical options are the only available treatment for severe POP. In the US, over 300,000 POP surgeries are performed annually for symptomatic POP repair and can include the use of native tissue, synthetic meshes, and acellular biologic grafts (ABGs). Unfortunately, these materials do not currently perform well. Over 40% of vaginal POP surgeries using native tissue fail within 2 years. Synthetic meshes carry significant safety risks including chronic infection, nerve and tissue damage, and genital tearing; these risks are so serious that the use of surgical mesh was recently banned in the US and several other countries. Currently available ABGs have high recurrence rates and complications can include graft mechanical failure, host-integration failure, and infection. Despite these issues, surgeons still support the use of current commercially available ABGs for POP because ABGs have higher cure rates than surgical methods that use native tissue.BioAesthetics is developing a transformative, polymer-strengthened ABG for use in POP surgeries for women with severe POP. Our customer discovery identified mechanical strength as the key feature needed for improving ABGs, thus, we developed patent-pending tissue engineering techniques for decellularization, to make ABGs, and for polymer impregnation, which enhances the ABGandapos;s mechanical properties. Our strengthened ABG simultaneously provides an allogeneic scaffold for patient-mediated tissue regeneration while countering the onset of complications due to graft mechanical failure, improving the safety and efficacy of POP surgery. In this Phase I project BioAesthetics is assessing the feasibility of this innovative product for use in POP corrective surgeries by first focusing on determining the mechanical strength of our polymer-strengthened ABG both pre- and post-implantation in a rodent model.Successful completion of this project will validate the feasibility of our product and generate proof-of-concept data to serve as a foundation for future efforts. A subsequent Phase II project will focus on further developing the product, expanding preclinical testing in additional large animal models of POP, and performing necessary biocompatibility work for an FDA submission. Our ultimate goal is to develop a novel ABG that changes the clinical paradigm for POP surgical repairs, resulting in improved outcomes and improved health and quality of life for women with severe POP.NARRATIVE BioAesthetics is creating an acellular biologic graft for use in pelvic organ prolapse (POP) repair surgeries with enhanced strength from the addition of a biocompatible, biodegradable, tunable hydrogel within the graft itself. Our novel approach simultaneously provides an allogeneic scaffold for patient-mediated tissue regeneration while countering potential complications resulting from graft mechanical failure during the course of wound healing.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

5 SBIR/STTR records share this UEI (2021–2023). Reported award amounts total $3,078,638. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services, National Science Foundation

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.